US8816242098
© PR Newswire
04.02.2026
TEVA
LISTED
NYSE
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
News Preview
Health Canada approves PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg.PrAJOVY® increases availability across age groups as the first and only calcitonin gene-related peptide (CGRP) antago...
Themefolio
Profiler
Peergroup
© PR Newswire
06.11.2025
TEVA
LISTED
NYSE
Teva Canada Welcomes RAMQ Reimbursement Update Supporting Access to ADHD Treatments
News Preview
MONTRÉAL, Nov. 6, 2025 /CNW/ - Teva Canada welcomes the recent announcement from Québec's Ministry of Health regarding changes to the reimbursement framework for extended-release methylphenidate products. Effective December 11, 2025, the Régie de l'assurance maladie du Québec (RAMQ) will apply the "lowest price"...
Themefolio
Profiler
Peergroup
© PR Newswire
14.03.2025
TEVA
LISTED
NYSE
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
News Preview
HONG KONG, March 14, 2025 /PRNewswire/ -- Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Kerry Pharma's extensive logistics (fourth-party logistics, 4PL) distribution capabilities, this collaboration aims to enhance Teva's pharmaceutical distribut...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
18.02.2025
TEVA
LISTED
NYSE
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© Globe Newswire
29.01.2025
TEVA
LISTED
NYSE
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
News Preview
2025 Outlook *...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
TEVA
LISTED
NYSE
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
News Preview
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that t...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
TEVA
LISTED
NYSE
Teva annonce un partenariat en vue de commercialiser le candidat biosimilaire de Formycon à Eylea® (aflibercept) dans la majeure partie de l’Europe et en Israël
News Preview
TEL AVIV, Israël, 14 janv. 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, filiale de Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA) annonce ce jour la conclusion d’un partenariat stratégique avec Klinge Biopharma GmbH, ci-après « Klinge », et Formycon AG (FSE : FYB) pour la commercialisation semi exclusive de FY...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
TEVA
LISTED
NYSE
Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel
News Preview
TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) today announced that it has entered into a strategic collaboration with Klinge Biopharma GmbH (Klinge) and Formycon AG (FSE: FYB) for the semi-exclusive commercialization of FYB203...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.12.2024
TEVA
LISTED
NYSE
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
TEVA
LISTED
NYSE
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
News Preview
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva wi...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2024
TEVA
LISTED
NYSE
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
News Preview
TEL AVIV, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Today, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that it has entered into an agreement with JKI, established by the fund managed and operated by J-Will, whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be tra...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
TEVA
LISTED
NYSE
Teva présente des données positives sur l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) pour la prévention de la migraine épisodique chez les enfants et les adolescents dans le cadre de l’essai clinique de phase III SPACE
News Preview
TEL AVIV, Israël, 04 déc. 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA) a présenté les résultats positifs de son étude de phase III SPACE évaluant l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) dans la prévention de la migraine épisodique chez les enfants et les adolescents âgés de 6 à...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
04.12.2024
TEVA
LISTED
NYSE
Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial
News Preview
TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented positive data from its Phase 3 SPACE study evaluating the efficacy and safety of AJOVY® (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years.1 The trial showed statistically...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2024
TEVA
LISTED
NYSE
Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference
News Preview
TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva’s Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, D...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
TEVA
LISTED
NYSE
Teva to Present at the Jefferies London Healthcare Conference
News Preview
TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2024
TEVA
LISTED
NYSE
Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
News Preview
For an accessible version of this Press Release, please visit www.tevapharm.com...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.11.2024
TEVA
LISTED
NYSE
Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
News Preview
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic diso...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.11.2024
TEVA
LISTED
NYSE
Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
News Preview
TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evalu...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.10.2024
TEVA
LISTED
NYSE
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
News Preview
REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.10.2024
TEVA
LISTED
NYSE
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
News Preview
TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab).1...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2024
TEVA
LISTED
NYSE
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
News Preview
TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients with Tardive Dyskinesia (TD) was associated with long term improvement of TD...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2024
TEVA
LISTED
NYSE
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
News Preview
TEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.09.2024
TEVA
LISTED
NYSE
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
News Preview
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today presented data informing clinical strategies for switching patients to UZEDY®, an extended-release injectable suspension of risperidone for subcutaneous use every one...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.09.2024
TEVA
LISTED
NYSE
Teva to Present at the Bank of America 2024 Global Healthcare Conference
News Preview
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 Global Healthcare Conference on Thursday, September 19, 2024. The presentation will begin at 8.15 A.M. British summer time (3.15 A.M...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
TEVA
LISTED
NYSE
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time....
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
TEVA
LISTED
NYSE
Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance
News Preview
For an accessible version of this Press Release, please visit www.tevapharm.com...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
